282 related articles for article (PubMed ID: 32131777)
1. Serum miRNAs, a potential prognosis marker of loco-regionally advanced nasopharyngeal carcinoma patients treated with CCRT.
Zhang Z; Huang J; Wang G; Jin F; Zheng J; Xiao H; Lei L; Luo J; Chen C
BMC Cancer; 2020 Mar; 20(1):183. PubMed ID: 32131777
[TBL] [Abstract][Full Text] [Related]
2. Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis.
Tan TH; Soon YY; Cheo T; Ho F; Wong LC; Tey J; Tham IWK
Radiother Oncol; 2018 Oct; 129(1):10-17. PubMed ID: 29555182
[TBL] [Abstract][Full Text] [Related]
3. A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma.
Liu N; Cui RX; Sun Y; Guo R; Mao YP; Tang LL; Jiang W; Liu X; Cheng YK; He QM; Cho WC; Liu LZ; Li L; Ma J
Int J Cancer; 2014 Mar; 134(6):1359-68. PubMed ID: 23999999
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
[TBL] [Abstract][Full Text] [Related]
5. Identification of a 7-microRNA signature in plasma as promising biomarker for nasopharyngeal carcinoma detection.
Zhang H; Zou X; Wu L; Zhang S; Wang T; Liu P; Zhu W; Zhu J
Cancer Med; 2020 Feb; 9(3):1230-1241. PubMed ID: 31856390
[TBL] [Abstract][Full Text] [Related]
6. Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case-control study.
Li Y; Chen QY; Tang LQ; Liu LT; Guo SS; Guo L; Mo HY; Chen MY; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Shao JY; Sun Y; Tan J; Chen S; Ma J; Zhao C; Mai HQ
BMC Cancer; 2017 Aug; 17(1):567. PubMed ID: 28836950
[TBL] [Abstract][Full Text] [Related]
7. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
[TBL] [Abstract][Full Text] [Related]
8. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial.
Yang Q; Cao SM; Guo L; Hua YJ; Huang PY; Zhang XL; Lin M; You R; Zou X; Liu YP; Xie YL; Wang ZQ; Mai HQ; Chen QY; Tang LQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Li JB; Ling L; Guo X; Hong MH; Chen MY
Eur J Cancer; 2019 Sep; 119():87-96. PubMed ID: 31425966
[TBL] [Abstract][Full Text] [Related]
9. CD3+T-lymphocyte infiltration is an independent prognostic factor for advanced nasopharyngeal carcinoma.
Al-Rajhi N; Soudy H; Ahmed SA; Elhassan T; Mohammed SF; Khoja HA; Ghebeh H
BMC Cancer; 2020 Mar; 20(1):240. PubMed ID: 32199452
[TBL] [Abstract][Full Text] [Related]
10. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study.
Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma.
Setakornnukul J; Thephamongkhol K
BMC Cancer; 2018 Mar; 18(1):329. PubMed ID: 29587665
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis.
Liu N; Chen NY; Cui RX; Li WF; Li Y; Wei RR; Zhang MY; Sun Y; Huang BJ; Chen M; He QM; Jiang N; Chen L; Cho WC; Yun JP; Zeng J; Liu LZ; Li L; Guo Y; Wang HY; Ma J
Lancet Oncol; 2012 Jun; 13(6):633-41. PubMed ID: 22560814
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
[TBL] [Abstract][Full Text] [Related]
14. Baseline Low Prognostic Nutritional Index Predicts Poor Survival in Locally Advanced Nasopharyngeal Carcinomas Treated With Radical Concurrent Chemoradiotherapy.
Topkan E; Yucel Ekici N; Ozdemir Y; Besen AA; Mertsoylu H; Sezer A; Selek U
Ear Nose Throat J; 2021 Feb; 100(2):NP69-NP76. PubMed ID: 31184210
[TBL] [Abstract][Full Text] [Related]
15. Identification of two microRNA signatures in whole blood as novel biomarkers for diagnosis of nasopharyngeal carcinoma.
Wen W; Mai SJ; Lin HX; Zhang MY; Huang JL; Hua X; Lin C; Long ZQ; Lu ZJ; Sun XQ; Liu SL; Yang Q; Zhu Q; Wang HY; Guo L
J Transl Med; 2019 Jun; 17(1):186. PubMed ID: 31159814
[TBL] [Abstract][Full Text] [Related]
16. miR-29a/b enhances cell migration and invasion in nasopharyngeal carcinoma progression by regulating SPARC and COL3A1 gene expression.
Qiu F; Sun R; Deng N; Guo T; Cao Y; Yu Y; Wang X; Zou B; Zhang S; Jing T; Ling T; Xie J; Zhang Q
PLoS One; 2015; 10(3):e0120969. PubMed ID: 25786138
[TBL] [Abstract][Full Text] [Related]
17. Profiling plasma microRNA in nasopharyngeal carcinoma with deep sequencing.
Wang HY; Yan LX; Shao Q; Fu S; Zhang ZC; Ye W; Zeng YX; Shao JY
Clin Chem; 2014 May; 60(5):773-82. PubMed ID: 24563490
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma.
Lin M; You R; Liu YP; Zhang YN; Zhang HJ; Zou X; Yang Q; Li CF; Hua YJ; Yu T; Cao JY; Li JB; Mo HY; Guo L; Lin AH; Sun Y; Qian CN; Ma J; Mai HQ; Chen MY
Oral Oncol; 2018 May; 80():1-8. PubMed ID: 29706183
[TBL] [Abstract][Full Text] [Related]
19. The effect of adjuvant chemotherapy on survival in patients with residual nasopharyngeal carcinoma after undergoing concurrent chemoradiotherapy.
Yang S; Lin S; Fu Q; Cai B; Kong F; Huang G; Li F; Wang H
PLoS One; 2015; 10(3):e0120019. PubMed ID: 25799566
[TBL] [Abstract][Full Text] [Related]
20. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma.
Zhong Q; Zhu X; Li L; Qu S; Liang Z; Zeng F; Pan X
Oncotarget; 2017 Jun; 8(24):39683-39694. PubMed ID: 28147309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
